ProQR Therapeutics to Post Q2 2024 Earnings of ($0.12) Per Share, HC Wainwright Forecasts (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ:PRQRFree Report) – Investment analysts at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a note issued to investors on Thursday, March 14th. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will earn ($0.12) per share for the quarter. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.38) per share.

Separately, StockNews.com upgraded ProQR Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, March 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, ProQR Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $3.72.

Read Our Latest Stock Analysis on ProQR Therapeutics

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR opened at $2.56 on Monday. The business’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $1.75. ProQR Therapeutics has a 52 week low of $1.11 and a 52 week high of $3.85. The firm has a market cap of $208.27 million, a price-to-earnings ratio of -6.56 and a beta of 0.20. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.68 and a current ratio of 4.68.

Institutional Trading of ProQR Therapeutics

A number of hedge funds have recently modified their holdings of the company. Boothbay Fund Management LLC lifted its position in shares of ProQR Therapeutics by 6.0% in the 1st quarter. Boothbay Fund Management LLC now owns 95,745 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 5,460 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of ProQR Therapeutics by 164.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,796 shares during the period. BNP Paribas Financial Markets lifted its position in shares of ProQR Therapeutics by 137.3% in the 4th quarter. BNP Paribas Financial Markets now owns 15,901 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 9,200 shares during the period. Belvedere Trading LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $42,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of ProQR Therapeutics by 18.5% during the 1st quarter. Cubist Systematic Strategies LLC now owns 101,003 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 15,756 shares during the period. Institutional investors own 26.15% of the company’s stock.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Further Reading

Earnings History and Estimates for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.